← Back to Screener
Immunocore Holdings plc American Depositary Shares (IMCR)
Price$31.38
Favorite Metrics
Price vs S&P 500 (26W)-10.90%
Price vs S&P 500 (4W)-0.50%
Market Capitalization$1.60B
All Metrics
P/CF (Annual)62.82x
Book Value / Share (Quarterly)$7.52
P/TBV (Annual)9.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)40.67%
Cash Flow / Share (Quarterly)$-0.19
Price vs S&P 500 (YTD)-11.49%
Gross Margin (TTM)98.73%
Net Profit Margin (TTM)-8.88%
EPS (TTM)$-0.71
10-Day Avg Trading Volume0.44M
EPS Excl Extra (TTM)$-0.71
Revenue Growth (5Y)67.77%
EPS (Annual)$-0.71
ROI (Annual)-4.59%
Gross Margin (Annual)98.73%
Net Profit Margin (5Y Avg)-114.48%
Cash / Share (Quarterly)$17.05
Revenue Growth QoQ (YoY)24.30%
ROA (Last FY)-3.33%
Revenue Growth TTM (YoY)28.95%
EBITD / Share (TTM)$-0.44
ROE (5Y Avg)-25.99%
Operating Margin (TTM)-11.34%
Cash Flow / Share (Annual)$-0.30
P/B Ratio4.21x
P/B Ratio (Quarterly)4.52x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.82x
Net Interest Coverage (TTM)-176.01x
ROA (TTM)-3.32%
EPS Incl Extra (Annual)$-0.71
Current Ratio (Annual)4.04x
Quick Ratio (Quarterly)3.81x
3-Month Avg Trading Volume0.40M
52-Week Price Return17.53%
EV / Free Cash Flow (Annual)73.32x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$169.97
P/S Ratio (Annual)4.01x
Asset Turnover (Annual)0.37x
52-Week High$40.71
Operating Margin (5Y Avg)-119.14%
EPS Excl Extra (Annual)$-0.71
CapEx CAGR (5Y)7.17%
26-Week Price Return-6.91%
Quick Ratio (Annual)3.94x
13-Week Price Return-3.06%
Total Debt / Equity (Annual)1.03x
Current Ratio (Quarterly)4.04x
Enterprise Value$1,529.225
Revenue / Share Growth (5Y)62.02%
Asset Turnover (TTM)0.37x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.83x
Pretax Margin (Annual)-4.77%
Cash / Share (Annual)$17.05
3-Month Return Std Dev35.55%
Net Income / Employee (TTM)$-0
ROE (Last FY)-9.32%
Net Interest Coverage (Annual)-25.02x
EPS Basic Excl Extra (Annual)$-0.71
P/FCF (TTM)34.88x
Receivables Turnover (TTM)5.84x
EV / Free Cash Flow (TTM)519.48x
Total Debt / Equity (Quarterly)1.03x
EPS Incl Extra (TTM)$-0.71
Receivables Turnover (Annual)5.84x
ROI (TTM)-4.56%
P/S Ratio (TTM)4.01x
Pretax Margin (5Y Avg)-121.73%
Revenue / Share (Annual)$7.95
Tangible BV / Share (Annual)$5.79
Price vs S&P 500 (52W)-12.30%
Year-to-Date Return-8.84%
5-Day Price Return-0.53%
EPS Normalized (Annual)$-0.71
ROA (5Y Avg)-14.14%
Net Profit Margin (Annual)-8.88%
Month-to-Date Return4.94%
Cash Flow / Share (TTM)$-1.24
EBITD / Share (Annual)$-0.44
Operating Margin (Annual)-11.34%
LT Debt / Equity (Annual)1.03x
P/CF (TTM)204.86x
ROI (5Y Avg)-18.48%
LT Debt / Equity (Quarterly)1.03x
EPS Basic Excl Extra (TTM)$-0.71
P/TBV (Quarterly)6.45x
P/B Ratio (Annual)4.52x
Inventory Turnover (TTM)0.83x
Pretax Margin (TTM)-4.77%
Book Value / Share (Annual)$7.52
Price vs S&P 500 (13W)-3.75%
Beta0.86x
P/FCF (Annual)76.78x
Revenue / Share (TTM)$7.91
ROE (TTM)-9.20%
52-Week Low$26.37
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMCRImmunocore Holdings plc American Depositary Shares | 4.01x | 28.95% | 98.73% | — | $31.38 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Immunocore is a commercial-stage biotechnology company that markets KIMMTRAK for unresectable and metastatic uveal melanoma. The company leverages its proprietary ImmTAX platform to develop a pipeline of candidates across oncology, infectious disease, and autoimmune disorders, including Brenetafusp and other clinical and pre-clinical programs.